Lungs News and Research

RSS

New NHGRI funding plan sharpens focus of Genome Sequencing Program on medical apps

A new funding plan by the National Human Genome Research Institute (NHGRI) sharpens the focus of its flagship Genome Sequencing Program on medical applications. In addition to continuing on-going studies, the four-year, $416 million plan launches new efforts to find causes of rare inherited diseases and accelerate the use of genome sequence information in the medical care of patients.

7 Dec 2011

TAU develops tumor destruction method that also creates immunity

Even when surgical tumor removal is combined with a heavy dose of chemotherapy or radiation, there's no guarantee that the cancer will not return. Now researchers at Tel Aviv University are strengthening the odds in favor of permanent tumor destruction - and an immunity to the cancer's return - with a new method of tumor removal.

7 Dec 2011

New alveoli continue to be formed as lungs grow

A ground-breaking international study into the ways lungs grow and develop has challenged existing medical understanding that our lungs are completely formed by the age of three.

7 Dec 2011

UK researchers to study differences in cancer survival in Appalachia

University of Kentucky researchers recently received a $225,000 grant to study the differences in cancer survival in Appalachia.

6 Dec 2011

Cameron says all NHS patients should share their medical data for research

According to British Prime Minister David Cameron, every NHS patient should be a “research patient” with their medical details “opened up” to private healthcare firms. The PM announced that all those who use the NHS in England will be helping in the fight against disease by helping advance research. He hopes the result will be that patients get faster access to new treatments and Britain's life sciences sector will become a world leader.

6 Dec 2011

Dust storms have adverse effect on hospital EDs for COPD

A new study published in the journal Respirology reveals that dust storms have an adverse effect on emergency hospital admission for chronic lung disease, often known as chronic obstructive pulmonary disease.

6 Dec 2011

Genetic variation predicts survival chances of ovarian cancer

Yale Cancer Center researchers have shown that a tiny genetic variation predicts chances of survival and response to treatment for patients with ovarian cancer.

5 Dec 2011

Plasma can inactivate and prevent replication of adenoviruses

Life-threatening viruses such as HIV, SARS, hepatitis and influenza, could soon be combatted in an unusual manner as researchers have demonstrated the effectiveness of plasma for inactivating and preventing the replication of adenoviruses.

5 Dec 2011

New technique allows production of medically useful amounts of endoderm cells from human PSCs

Scientists in Canada have overcome a key research hurdle to developing regenerative treatments for diabetes and liver disease with a technique to produce medically useful amounts of endoderm cells from human pluripotent stem cells. The research, published in Biotechnology and Bioengineering, can be transferred to other areas of stem cell research helping scientists to navigate the route to clinical use known as the 'valley of death'.

3 Dec 2011

Study directly quantifies magnitude of asthma among WTC responders

The American Journal of Industrial Medicine recently published a study showing that World Trade Center (WTC) responders suffer from asthma at more than twice the rate of the general U.S. population as a result of their exposure to the toxic dust from the collapse of the WTC towers in 2001. Preliminary study results were previously presented in CHEST in 2009.

3 Dec 2011

Promising new agent against sarcomas affecting children

MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla. Their findings, recently appearing in Molecular Cancer Therapeutics, published by the American Association for Cancer Research, suggest that a badly needed new agent against sarcomas - especially sarcomas affecting children - may be at hand.

3 Dec 2011

MK 1775 shows promise against sarcomas

MK 1775, a small, selective inhibitor molecule, has been found to be active against many sarcomas when tested by researchers at Moffitt Cancer Center in Tampa, Fla.

3 Dec 2011

First Edition: December 2, 2011

In today's headlines, reports on congressional efforts to extend a payroll tax break and other work Congress must do before the end of the year -- including the Medicare doc fix.

2 Dec 2011

Treatments for lymphoma with no side effects

Larry Conrad went in for his annual physical on his 50th birthday. During his exam, his doctor found swollen lymph nodes in his armpits and groin. Conrad had a cough and said he'd lost weight because he 'felt full all the time'. His doctor ordered a series of tests, and Conrad was diagnosed with Non-Hodgkin's lymphoma, the most common type.

2 Dec 2011

Doctors underestimate worldwide burden of CPA, says public health expert

Researchers have discovered that over a million people worldwide diagnosed with TB go on to develop an incurable but manageable fungal infection which is usually left untreated because it is mistaken for a recurrence of the disease.

2 Dec 2011

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

AVEO Pharmaceuticals, Inc. and Boehringer Ingelheim today announced that they have entered into an agreement for large-scale process development and clinical manufacturing of ficlatuzumab, AVEO's novel HGF inhibitory antibody that is currently in Phase 2 clinical development in patients with non-small cell lung cancer.

2 Dec 2011

Insights into causes of Idiopathic Pulmonary Fibrosis

Tracking individual cells within the lung as they move around and multiply has given Duke University researchers new insights into the causes of Idiopathic Pulmonary Fibrosis (IPF) a disease which can only be treated now by lung transplantation.

1 Dec 2011

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.

1 Dec 2011

BUSM, BMC anesthesiologists win APSF's Ellison C. Pierce Award

For the second consecutive year, anesthesiologists from Boston Medical Center (BMC) and Boston University School of Medicine (BUSM) have received the prestigious Ellison C. Pierce Award for the Best Scientific Exhibit in Patient Safety from the Anesthesia Patient Safety Foundation.

1 Dec 2011

Idera regains global rights to IMO-2055 from Merck KGaA for treatment of cancer

Idera Pharmaceuticals, Inc. today announced that it has regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as part of an agreed-upon termination of its oncology collaboration with Merck KGaA, Darmstadt, Germany.

1 Dec 2011